SHSoroosh Hamzeh

Soroosh Hamzeh

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Soroosh Hamzeh has a total of 7 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Precision theranostics in oncology: integrating antibody-drug conjugates, radioimmunotherapy, and immuno‑PET for adaptive cancer care

    by Jingyi Wang, Qian Zhang, Yang Cao, Chunbo Wang, Soroosh Hamzeh

    The century-old vision of a "magic bullet" in oncology is being realized through the paradigm of precision theranostics, which formally integrates targeted delivery, cytotoxic action, and non-invasive imaging into a unified clinical feedback loop. This review synthesizes the cutting-edge convergence of three interdependent pillars: antibody-drug conjugates (ADCs), which act as Trojan horses delivering potent cytotoxic payloads; radioimmunotherapy (RIT), which harnesses the power of radionuclides for crossfire-mediated cytotoxicity; and advanced molecular imaging, which orchestrates patient stratification and early response assessment. We dissect the mechanistic innovations in ADC design, the renaissance of RIT with novel isotopes and targets, and the pivotal role of immuno-PET in enabling an "image-to-treat" paradigm. Furthermore, we explore the synergistic frontier of rationally combining ADCs and RIT to overcome resistance through multi-mechanistic attacks, leveraging radiation for payload activation, and priming the tumor microenvironment. Despite challenges in toxicity management, radiopharmaceutical supply, and regulatory frameworks, the integration of these modalities, guided by artificial intelligence and functional imaging, heralds a new era of dynamic, personalized, and adaptive cancer therapy. This integrative approach promises to convert tumor heterogeneity from a fundamental obstacle into a targetable vulnerability; however, this promise must be tempered by clinical examples in which heterogeneity undermined otherwise promising targeted approaches (for example, subclonal RAS mutations limiting benefit from anti-EGFR monoclonal antibodies in colorectal cancer). We therefore emphasize lesion-level imaging and adaptive, imaging-guided sequencing as realistic, evidence-based mechanisms by which theranostics can reduce the impact of intratumoral heterogeneity and improve the chance of durable benefit.


  • Open Access

    Prevalence of Vancomycin-Resistant Van A and Van B Genes in ESKAPE Gram-Positive Bacteria Isolated from Hospitalized Patients in Mashhad, Iran

    by Soroosh Hamzeh, Seyed Reza Hosseini, Tohid Javaheri, Negar Rajabi

    Introduction: The ESKAPE group, comprising Escherichia coli, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterococcus faecium, is known for its role in hospital-acquired infections and its growing resistance to antimicrobial agents. This resistance complicates treatment options, particularly with last-resort antibiotics, such as vancomycin. This study aims to determine the prevalence of vancomycin-resistant genes (Van A and Van B) in Staphylococcus aureus and Enterococcus species isolated by polymerase chain reaction (PCR) method from hospitalized patients in Mashhad, Iran. Materials and Methods: A total of 1000 clinical samples were collected over six months from hospitalized patients in four hospitals in Mashhad, Iran. The samples included blood, urine, wound swabs, and respiratory secretions. Staphylococcus aureus and Enterococcus isolates were identified through standard microbiological tests. Vancomycin susceptibility was assessed using the E-test method. The presence of vancomycin-resistant genes (Van A and Van B) was determined by PCR method. Results: Out of a total of 98 bacterial isolates, 77 were identified as Staphylococcus aureus and 21 as Enterococcus species. Among the Enterococcus isolates, 15 were identified as Enterococcus faecium and 6 as Enterococcus faecalis. Vancomycin resistance genes were detected in 7 isolates in total, with 6 of these isolates harboring the Van A gene and 1 carrying the Van B gene. Conclusion: The study reveals 40% and 1.3% prevalences of vancomycin resistance in Enterococcus faecium and Staphylococcus aureus isolates, respectively. These findings underscore the critical need for vigilant antibiotic stewardship and the implementation of appropriate treatment strategies to effectively manage infections caused by these resistant pathogens.